Skip to main content

Table 2 Baseline Characteristics of included populations

From: Efficacy and safety outcomes in novel oral anticoagulants versus vitamin-K antagonist on post-TAVI patients: a meta-analysis

Study

 

Age

Female

BMI

Diabetes Mellitus

I

C

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

Seeger et al., 2017 [26]

Apixaban (n = 141)

VKA (n = 131)

82.1 (5.3)

80.5 (6.3)

50.4% (71)

48.1% (63)

27.2 (4.2)

27.4 (5.1)

32.6% (46)

32.0% (42)

Geis et al., 2018 [27]

NOAC (n = 154)

VKA (n = 172)

83.1 (5.3)

83.0 (4.9)

50.6% (78)

54.7% (94)

26.6 (5.3)

27.0 (5.3)

31.0% (47)

33% (57)

Jochheim et al., 2019 [28]

NOAC (n = 326)

VKA (n = 636)

81.6 (6.7)

81.1 (6.1)

52.1% (170)

52.7% (335)

26.3 (5.2)

26.6 (4.9)

28.8% (94)

34.1% (217)

Butt et al., 2019 [29]

DOAC (n = 219)

VKA (n = 516)

83.0 (1.8)

82.0 (2.0)

46.1% (101)

46.3% (239)

N/A

N/A

17.8% (39)

24.2% (125)

Kalogeras et al., 2019 [31]

DOAC (n = 115)

VKA (n = 102)

81.9 (6.3)

82.5 (5.8)

41% (47)

42.2% (43)

27.3 (5.8)

25.9 (5.8)

24.3% (28)

26.8% (28)

Kosmidou et al., 2019 [30]

NOAC (n = 155)

VKA (n = 778)

82.8 (6.7)

34.4% (321)

28.4 (6.1)

35.3% (330)

GALILEO, 2020 [32]

NOAC (n = 826)

VKA (n = 818)

80.4 (7.1)

80.8 (6.0)

48.4% (400)

50.5% (413)

28.1 (5.5)

28.2 (5.7)

28.6% (236)

28.7% (235)

Study

Chronic Renal Failure

COPD

Coronary Heart disease

History of MI

History of Cardiac surgery

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

Seeger et al., 2017 [26]

44.7% (63)

48.9% (64)

N/A

N/A

66.0% (93)

58.8% (77)

17.7% (25)

21.4% (28)

12.8% (18)

12.2% (16)

Geis et al., 2018 [27]

N/A

N/A

N/A

N/A

52.0% (80)

51.0% (88)

N/A

N/A

9.7% (15)

8.0% (13)

Jochheim et al. 2019 [28]

53.3% (174)

44.3% (282)

20.6% (67)

21.9% (139)

N/A

N/A

14.1% (45)

15.4% (94)

8.9% (29)

12.1% (77)

Butt et al., 2019 [29]

5.9% (13)

14.2% (73)

21.0% (46)

16.9% (87)

N/A

N/A

N/A

N/A

N/A

N/A

Kalogeras et al., 2019 [31]

N/A

N/A

N/A

N/A

N/A

N/A

14.8% (17)

10.3% (11)

71.3% (82)

46.1% (47)

Kosmidou et al.,2019 [30]

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

GALILEO, 2020 [32]

N/A

N/A

13.3% (110)

10.8% (88)

39.3% (325)

37.3% (305)

N/A

N/A

N/A

N/A

Study

Recent PCI

Haemoglobin pre-TAVI/g/dl

Aortic Valve Area cm2

Peripheral or cerebral vascular disease

History of stroke or intracerebral bleeding

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

Seeger et al., 2017 [26]

N/A

N/A

N/A

N/A

N/A

N/A

82.9% (117)

88.5% (116)

11.3% (16)

14.5% (19)

Geis et al., 2018 [27]

1.0% (2)

1.0% (2)

12.1 (1.8)

11.8 (1.6)

0.7 (0.2)

0.7 (0.2)

N/A

N/A

16.0% (24)

15.0% (25)

Jochheim et al. 2019 [28]

32.5% (106)

29.9% (190)

12.2 (1.8)

12.3 (1.9)

0.7 (0.2)

0.7 (0.2)

4.0% (13)

11.5% (73)

20.6% (67)

21.9% (139)

Butt et al., 2019 [29]

N/A

N/A

N/A

N/A

N/A

N/A

10.1% (22)

8.9% (46)

24.7% (54)

15.1% (78)

Kalogeras et al., 2019 [31]

27% (31)

23.5% (24)

N/A

N/A

0.68 (0.30)

0.67 (0.29)

N/A

N/A

40.2% (41)

31.3% (36)

Kosmidou et al.,2019 [30]

49.1% (458)

N/A

N/A

 

22% (206)

22.0% (205)

GALILEO, 2020 [32]

N/A

N/A

N/A

N/A

1.8 (0.6)

1.9 (0.5)

10.0% (83)

10.0% (82)

6.2% (51)

4.3% (35)

Study

Atrial Fibrillation

Hypertension

CHA2DS2-VASc Score

STS Score for mortality

Ejection Fraction≤50%

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

NOAC

VKA

Seeger et al., 2017 [26]

100% (141)

100% (131)

N/A

N/A

5.0 (1.2)

4.9 (1.1)

7.5 (5.2)

7.9 (6.3)

N/A

N/A

Geis et al., 2018 [27]

94.0% (145)

94.0% (161)

95% (147)

92% (158)

4.6 (1.2)

4.8 (1.3)

4.1 (1.9)

4.4 (2.4)

29% (44)

33.0% (57)

Jochheim et al. 2019 [28]

62.0% (202)

75.2% (478)

89.9% (293)

89.5% (569)

≥2:93.6% (n = 305)

≥2: 96.1% (n = 611)

4.5 (1.1)

4.5 (1.1)

39.9% (130)

39.3% (250)

Butt et al., 2019 [29]

100% (219)

100% (516)

87.2% (191)

88.6% (457)

5.0 (1.4)

4.0 (1.3)

N/A

N/A

N/A

N/A

Kalogeras et al., 2019 [31]

68.7% (79)

59.8% (61)

N/A

N/A

N/A

N/A

N/A

N/A

9.6% (11)

3.9% (4)

Kosmidou et al.,2019 [30]

100% (933)

91.7% (856)

5.6 (1.3)

8.2 (4.2)

N/A

GALILEO, 2020 [32]

10.4% (87)

11.3% (94)

87.2% (720)

85.2% (697)

4.5 (1.3)

4.6 (1.2)

4.0 (3.2)

4.3 (3.5)

57.4 (11.2)a

58.2 (11.2)1

  1. Values presented in No. of events (Total) or % (No. of event)
  2. adenotes for value (SD)
  3. I Intervention
  4. C Control
  5. COPD Chronic Obstructive Pulmonary Disease
  6. MI Myocardial Infarction
  7. PCI Percutaneous Cardiac Intervention